Authors

Shai Friedland, MD

Latest:

Dr. Friedland on a Multimodal Screening Blood Test to Detect CRC

Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

Katherine Walsh, MD

Latest:

Preparing and Delivering a Virtual Learning Session

Strategies are important to optimize learning in the virtual environment including speaker preparation, creating a virtual learning climate, and encouraging and enhancing interaction.

Courtney R. Arn, APRN-CNP

Latest:

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Cristina Saura Manich, MD, PhD

Latest:

Dr Manich on the ReDiscover Study of RLY-2608 in PIK3CA-Mutant Advanced Solid Tumors

Cristina Saura Manich, MD, PhD, discusses the phase 1 ReDiscover study evaluating RLY-2608 in patients with PIK3CA-mutated advanced breast cancer and other solid tumors.

Andrew J. Wagner, MD, PhD

Latest:

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.

Cara A. Mathews, MD

Latest:

Dr Mathews on Maintenance Olaparib in Ovarian Cancer

Cara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.

Srikala Sridhar, MD, MSc, FRCPC

Latest:

Dr Sridhar on the Importance of Patient Selection for Benefit With Avelumab in PSCC

Srikala Sridhar, MD, MSc, FRCPC, discusses efficacy findings from the ALPACA study and the necessity of improved patient selection for checkpoint inhibitors in PSCC

Pashna Munshi, MD

Latest:

Current Treatment Options for Patients with Steroid-Refractory Acute GVHD

Closing her discussion, Dr Pashna Munshi reviews recent data on the available treatment options for patients with steroid-refractory acute GVHD.

Madhurima Anne, MD

Latest:

Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast Cancer

Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.

Christian Grommes, MD

Latest:

Dr Grommes on the Addition of Ibrutinib to R-MPV Induction in Newly Diagnosed PCNSL

Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.

David L. Porter, MD, University of Pennsylvania

Latest:

Back to the Future: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Sarah Sewaralthahab, MD, MPH

Latest:

Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.

Ayesha Alvero, MD, MSc

Latest:

Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models

Ayesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.

Laura W. Dillon, PhD, FACMG

Latest:

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

Justin Kaner, MD

Latest:

Menin Inhibitors for AML: A Roundtable on the Latest Advances

Justin Kaner, MD, discusses the latest advances surrounding menin inhibitors in acute myeloid leukemia.

Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages

Latest:

Nuvisertib Plus Momelotinib Is Safe, Produces Spleen, Symptom, Anemia Responses in R/R Myelofibrosis

Nuvisertib demonstrated clinical activity as both a single agent and in combination with momelotinib for patients with relapsed/refractory myelofibrosis.

asey M. Cosgrove, MD

Latest:

Dr Cosgrove on T-DXd Treatment in Ovarian Cancer

Casey M. Cosgrove, MD, discusses treatment with the ADC T-DXd in patients with ovarian cancer.

Ronit Slotky, PhD

Latest:

Dr. Slotky on Evolving Treatment with Stem Cell Transplants in Multiple Myeloma

The US Oncology Network

Latest:

The US Oncology Network Expands its Tennessee Service Area as Tennessee Cancer Specialists Joins The Network

Tennessee Cancer Specialists, the third largest oncology practice in the state, strengthens its ability to deliver cutting-edge advanced care by joining The Network.

Oliver Van Oekelen, MD, PhD

Oliver Van Oekelen, MD, PhD is a bioinformatics-trained

Latest:

Dr Van Oekelen on the Role of S100A8/A9 in Promoting T-Cell Exhaustion in Multiple Myeloma

Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.